title: [The Use of Arginine Vasopressin and PhosphodiesteraseIII Inhibitor for Circulatory Shock after the Resection of a Massive Adrenal Pheochromocytoma].
abstract: A 72-year-old man developed hypertensive crisis five month previously, and was diagnosed with massive adrenal pheochromocytoma, with a diameter of 14.5 cm. Preoperative echocardiography revealed normal cardiac function. The open abdominal surgery was performed under general anesthesia. During manipulation of the tumor he developed hypertension and tachycardia. Severe hypotension (50/25 mmHg) and mild bradycardia (70 beats x min(-1)) followed the resection of the tumor. In addition to volume replacement noradrenaline and adrenaline were administered, but the systolic blood pressure rose only to 60-70 mmHg. In order to treat vasodilatory shock, we started to administer arginine vasopressin infusion at 0.03 units x min(-1). His systolic blood pressure rose to 90 mmHg. The patient was transferred to the intensive care unit (ICU) postoperatively. The echocardiography revealed diffuse hypokinetic cardiac function. In order to treat cardiogenic shock, we started to administer olprinone (phosphodiesteraseIII inhibitor, infusion of 0.1 μg x kg(-1) x min(-1)). On postoperative day 2, circulatory shock improved and the patient was discharged from the ICU. In conclusion, circulatory shock after the resection of a massive pheochromocytoma was due to the down regulation of α and β adrenergic receptors. The non-adrenergic vasoconstrictor and inotrope were useful for this situation.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nagamine
authors.forename: Reiko
authors.initials: R
authors.lastname: Nishinarita
authors.forename: Kenji
authors.initials: K
authors.lastname: Mizutani
authors.forename: Takahisa
authors.initials: T
authors.lastname: Goto
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000601:surgery*; D000368:Aged; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D001794:Blood Pressure; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000378:metabolism; D006801:Humans; D008297:Male; D010673:Pheochromocytoma / Q000601:surgery*; D058987:Phosphodiesterase 3 Inhibitors / Q000627:therapeutic use*; D012769:Shock / Q000188:drug therapy*; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D058987:Phosphodiesterase 3 Inhibitors; D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3